The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials , growing closer to determining which will be considered safe and effective . 
One such candidate is in development by the American pharmaceutical company Pfizer , which announced along with its German partner Bio NTech on Saturday they proposed expanding Phase 3 clinical trials to include 44,000 participants and more diverse patient populations , including people as young as 16 . 
That 's up from the initial plan of 30,000 participants , a benchmark they plan to meet next week , according to a news release . 
Diversity matters : The proposal , which would need approval by the Food and Drug Administration , would allow the companies to collect more data on the safety and efficacy of the vaccine candidate while diversifying the pool of participants . 
Read the full story : 
